EXINI Diagnostics

Executive Summary

EXINI Diagnostics AB, founded in 1999 and headquartered in Lund, Sweden, is a pioneer in AI-driven automated analysis of diagnostic images. The company leverages deep learning algorithms developed at Lund University to provide automated quantification and interpretation for PSMA PET/CT, cardiac, brain, and bone scans. With over 800 clinical sites worldwide, EXINI's software enhances diagnostic accuracy, reduces reading time, and supports clinicians in personalized medicine decisions. The company's platforms are designed to integrate seamlessly into existing workflows, addressing the growing demand for precision diagnostics in oncology, cardiology, and neurology. As a private company with a proven track record, EXINI Diagnostics is well-positioned to capitalize on the expanding AI diagnostics market. The global shift towards value-based care and the increasing adoption of AI in radiology and nuclear medicine present significant growth opportunities. EXINI's established presence across multiple continents, combined with its focus on high-demand areas like prostate cancer imaging (PSMA), provides a competitive edge. However, the company faces competition from other AI imaging vendors and must navigate regulatory and reimbursement challenges. Nevertheless, its robust product portfolio and clinical validation underscore its potential for sustained growth.

Upcoming Catalysts (preview)

• Q2 2026FDA Clearance or CE Mark for Next-Generation AI Platform75% success
• H2 2026Strategic Partnership with Major Imaging OEM (e.g., Siemens, GE HealthCare) for Global Distribution60% success
• Q1 2027Publication of Pivotal Clinical Study Demonstrating Improved Outcomes in Prostate Cancer Management70% success